Follow-up Discussion of Serious Adverse Event OBA Protocol Number 705 - Amgen - Document - PDFSEARCH.IO

First Page	Meta Content
	Follow-up Discussion of Serious Adverse Event OBA Protocol Number 705 Add to Reading List Document Date: 2013-12-10 09:33:23 Open Document File Size: 746,99 KB Share Result on Facebook Facility M.D. University of Washington Phase I/II Clinical Study / M.D. University of Washington Phase I/II / / MedicalCondition Syncope / Abdominal pain / septic arthritis / Myocardial infarction / presumed HSV infection / Inflammatory Arthritis / Pulmonary emboli / disease modifying anti-rheumatic drugs / infection / rheumatoid arthritis / constipation / Cellulitis / gynecologic infection / Acute pyelonephritis / increased fatigue / itching / / MedicalTreatment incision / / Organization University of Washington Phase I/II Clinical Study / University of Washington Phase I/II / NIH office of Biotechnology Activities / IntraArticular Administration of tgAAC94 / Repeat Intra-Articular Administration of tgAAC94 / / Position investigator / private physician for presumed HSV infection / / Product prednisone / leflunomide / acyclovir / / Technology Biotechnology / / SocialTag Clinical research Research Pharmacology Design of experiments Amgen Etanercept Clinical trial Placebo Rheumatoid arthritis Medicine

Follow-up Discussion of Serious Adverse Event OBA Protocol Number 705Add to Reading List